Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Update

Quantum Biopharma Ltd. (NASDAQ:QNTM) saw a large growth in short interest in May. As of May 29th, there was short interest totaling 411,604 shares, a growth of 85.7% from the May 14th total of 221,665 shares. Based on an average daily trading volume, of 620,229 shares, the days-to-cover ratio is currently 0.7 days. Currently, 11.8% of the shares of the stock are short sold.

Institutional Investors Weigh In On Quantum Biopharma

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new position in Quantum Biopharma in the 4th quarter worth approximately $76,000. Jane Street Group LLC acquired a new stake in Quantum Biopharma during the 4th quarter valued at $80,000. Finally, Platform Technology Partners purchased a new stake in shares of Quantum Biopharma in the first quarter valued at $199,000. Hedge funds and other institutional investors own 1.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on QNTM shares. Weiss Ratings cut Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. Wall Street Zen lowered Quantum Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quantum Biopharma has an average rating of “Sell”.

Quantum Biopharma Stock Performance

QNTM traded down $0.05 during trading on Monday, reaching $3.78. The company had a trading volume of 52,363 shares, compared to its average volume of 343,363. The firm’s 50-day simple moving average is $4.98 and its 200 day simple moving average is $5.61. The company has a market cap of $14.43 million, a price-to-earnings ratio of -0.46 and a beta of 0.36. Quantum Biopharma has a 12-month low of $2.07 and a 12-month high of $38.25.

Quantum Biopharma (NASDAQ:QNTM) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.49).

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.